PMID- 11251362
OWN - NLM
STAT- MEDLINE
DCOM- 20010705
LR  - 20171101
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 30 Suppl 2
DP  - 2000
TI  - Low-molecular-weight heparins in the management of unstable angina.
PG  - 158-67; discussion 146-7
AB  - Low-molecular-weight heparins (LMWHs) are derivatives of unfractionated heparin 
      (UFH) and have a more favourable pharmacokinetic profile and a more predictable 
      anticoagulant effect than UFH. These features allow the subcutaneous injection of 
      weight-adjusted doses of LMWHs without monitoring of blood coagulation, and this 
      results in cost savings. Clinical trials have shown that combined therapy with 
      aspirin and LMWHs is significantly more effective than aspirin alone in reducing 
      the risk of cardiac events in the acute treatment of patients affected by 
      unstable angina. LMWHs have also been shown to be at least as safe and effective 
      as UFH in reducing the incidence of death and myocardial infarction in patients 
      with unstable angina. LMWHs appear to be at least as safe as UFH with regard to 
      major bleeding risk. When given as extended therapy, LMWHs have been shown to be 
      superior to placebo at 30 and 45 days, with an acceptable risk of bleeding. 
      Additionally, LMWHs can be used as a 'bridge' to revascularization in patients 
      for whom early invasive treatment is not readily available.
CI  - Copyright 2001 S. Karger AG, Basel
FAU - Agnelli, G
AU  - Agnelli G
AD  - Division of Internal and Cardiovascular Medicine, Department of Internal 
      Medicine, University of Perugia, Italy. agnellig@unipg.it
FAU - Sonaglia, F
AU  - Sonaglia F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/*drug therapy/mortality/surgery
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Combined Modality Therapy
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Hemorrhage/chemically induced
MH  - Heparin/administration & dosage/adverse effects/therapeutic use
MH  - Heparin, Low-Molecular-Weight/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Myocardial Infarction/mortality/prevention & control
MH  - Myocardial Revascularization
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/therapeutic use
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Risk
MH  - Treatment Outcome
RF  - 19
EDAT- 2001/03/17 10:00
MHDA- 2001/07/06 10:01
CRDT- 2001/03/17 10:00
PHST- 2001/03/17 10:00 [pubmed]
PHST- 2001/07/06 10:01 [medline]
PHST- 2001/03/17 10:00 [entrez]
AID - 54184 [pii]
AID - 10.1159/000054184 [doi]
PST - ppublish
SO  - Haemostasis. 2000;30 Suppl 2:158-67; discussion 146-7. doi: 10.1159/000054184.